Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01302
|
|||||
| Drug Name |
Levocetirizine
|
|||||
| Synonyms |
(-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Allergy [ICD11: 4A8Z] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H25ClN2O3
|
|||||
| Canonical SMILES |
C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
|
|||||
| InChI |
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
|
|||||
| InChIKey |
ZKLPARSLTMPFCP-OAQYLSRUSA-N
|
|||||
| CAS Number |
CAS 130018-77-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 388.9 | Topological Polar Surface Area | 53 | ||
| Heavy Atom Count | 27 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1.7
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:94559
|
|||||
| DT(s) Transporting This Drug | OAT4 | Transporter Info | Organic anion transporter 4 | Substrate | [2] | |
| References | ||||||
| 1 | Levocetirizine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.